Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01487109 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01487109 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 170 participants.
The verdict
NCT01487109, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB).
Interventions
- DRUG Placebo
- DRUG CTP-499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01487109
The ClinicalTrials.gov registry entry for NCT01487109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01487109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01487109 about?
NCT01487109 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients". This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin II recepto...
What is the current status of trial NCT01487109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2012-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01487109?
The interventions under investigation include: Placebo (DRUG), CTP-499 (DRUG).
Who is sponsoring clinical trial NCT01487109?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.